Can Gamma-glutamyl Transferase Predict Unhealthy Metabolic Phenotypes Among Healthcare Workers in Azar Cohort Study?

Mohammad Somi, Seyed Sina Zakavi, Alireza Ostadrahimi, Negin Frounchi, Neda Gilani, Sarvin Sanaie, and Elnaz Faramarzi

1Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
5Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

*Corresponding author: Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Email: sarvin_so2000@yahoo.com
**Corresponding author: Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Email: elnazfaramarzi849@gmail.com

Received 2021 December 03; Revised 2022 May 17; Accepted 2022 May 17.

Abstract

**Background:** Although various studies have assessed the correlation between gamma-glutamyl transferase (GGT) and cardiometabolic risk factors in obesity, no research has differentiated among metabolically-healthy obese (MHO) and metabolically unhealthy obese (MUHO), metabolically-healthy lean (MHL), and metabolically-unhealthy lean (MUHL).

**Objectives:** Accordingly, this study evaluated the correlation between GGT and cardiometabolic phenotypes among healthcare workers.

**Methods:** In this study, there were anthropometric measurements as well as the measurements of fasting blood sugar (FBS), GGT, cholesterol, triglyceride (TG), high lipoprotein density (HDL), and blood pressure in 1458 healthcare workers enrolled in the Azar Cohort Study. Metabolic syndrome (MetS) was defined according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III). Accordingly, the participants were divided into four cardiometabolic phenotypes.

**Results:** In this cross-sectional study, there was a significant difference in the prevalence of cardiometabolic phenotypes regarding the GGT tertiles (P ≤ 0.001). The highest prevalence of MHO was observed in the third GGT tertile. The mean waist circumference, TG, FBS, HDL, and systolic and diastolic blood pressure levels increased in the MHO, MUHO, and MHL groups in a dose dependent manner with an increase in the GGT tertiles (P < 0.05). In comparing the highest and lowest GGT tertile, the risk of MHO and MUHO increased by 2.84 (95%CI 2.01 - 4.01) and 9.12 (95%CI 5.54 - 15), respectively. However, the correlation between the GGT tertile and MUHL did not reveal a similar trend. The ROC curve shows the cutoff value of 18.5 U/L for GGT, which allowed us to distinguish between the MUHO and MHO individuals.

**Conclusions:** The findings revealed that GGT can indicate the risk of MetS as such, it can be used to detect at-risk MHO individuals and administer proper interventions.

**Keywords:** Cardiometabolic Phenotype, Gamma Glutamyl Transferase, Cohort Study, Metabolic Syndrome

1. Background

Gamma-glutamyl transferase (GGT), situated on the external surface of the plasma membrane, is a glycosylated protein produced by the epithelial cells of the intrahepatic bile ducts. GGT can be used as a marker for alcohol consumption status and hepatobiliary diseases such as non-alcoholic fatty liver disease (NAFLD). GGT is indirectly correlated with chronic inflammation and increased oxidative stress, which are closely connected to metabolic disorders (1, 2). Moreover, the high ranges of GGT are correlated with cardiovascular diseases, atherosclerosis, type 2 diabetes, chronic kidney disease (CKD), and metabolic syndrome (MetS) (1, 3). MetS encompass several metabolic risk factors, including central obesity, high blood pressure, increased blood glucose hyperglycemia, and low high-density lipoprotein (HDL) cholesterol. This syndrome is a major global public health problem since it increases the risk of malignancies, heart diseases, diabetes type II, and others (4).

There is a close relationship between serum GGT with insulin resistance and MetS components (5). Patients with MetS and high GGT are reported to be at a higher risk of cardiovascular disorders than individuals without MetS or...
patients with MetS and low GGT (6). Moreover, recent studies have documented a relationship between GGT and mortality (7-9). Some evidence demonstrates that the normal ranges of GGT are connected with increased cardiovascular diseases and all-cause mortality. This correlation was valid in both genders of normal and obese subjects, with or without cardiovascular diseases, after adjusting for intervening factors (7, 8). These findings imply that subjects with normal or elevated BMI may be metabolically healthy or unhealthy; hence, further studies are required to determine which biochemical parameters are connected with lower atherogenic and healthier metabolic health status in normal or obese individuals.

Although various studies have assessed the correlation between GGT and cardiometabolic risk factors in obesity, no research has differentiated among metabolically-healthy obese (MHO), metabolically-unhealthy obese (MUHO), metabolically-healthy lean (MHL), and metabolically-unhealthy lean (MUHL) individuals. Accordingly, GGT, as a simple, cost-effective test, is vital for the multi-marker approach in cardiovascular risk evaluation and can also be used to differentiate the metabolic subtypes (ie, cardiometabolic phenotype) (10-12).

2. Objectives

This is, while the correlation between GGT and cardiometabolic phenotype has not been investigated. Thus, this study examined the correlation between GGT and cardiometabolic phenotypes in healthcare workers in the Azar Cohort Study.

3. Methods

This cross-sectional study was conducted in 2020 by the Research Center for Liver, and Gastrointestinal Diseases of the Tabriz University of Medical Sciences using data obtained from healthcare workers enrolled in the Azar Cohort Study, a part of the Prospective Epidemiological Research Studies in Iran (PERSIAN) (13). The Azar Cohort Study was launched in 2014 to determine the risk factors of non-communicable diseases (NCDs) in East Azerbaijan province (14). We used data from 1,458 subjects of the cohort in the present study after obtaining written informed consent from all participants. The Ethics Committee of the Tabriz University of Medical Sciences, Tabriz, Iran (IR.TBZMED.REC.1400.627) approved this study.

We recruited participants from the Tabriz University of Medical Sciences, who were full-time and long-term contract employees aged 18 - 75 years and had no plan to retire in the next five years. A health professional was in charge of excluding the participants if they were pregnant or lactating or were diagnosed with disabling psychiatric disorders or physical illnesses. We also screened potential participants for not having a plan for retirement within the next five years.

3.1. Participants’ Demographic Characteristics

The questionnaires focused on the participants’ demographic characteristics, including gender, age, marital status, and level of education. Moreover, the individual’s personal habits such as drug consumption, smoking, hookah use, and alcohol consumption were recorded.

3.2. Anthropometric and Blood Pressure Measurements

The measured anthropometric data included weight, height, and body mass index (BMI; ratio of weight in kilograms to height in meters squared). The anthropometric measurements are described in detail elsewhere (13). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using a mercury sphygmomanometer (Riester Exacta 1350 Sphygmomanometer, Germany) in the sitting position after 10 minutes of rest. The averages of two measurements on each arm (at a two-minute interval) were used for the statistical analyses.

3.3. Biochemical Factors

Blood samples were extracted after the overnight fasting of at least 12 hours. Enzymatic methods were used to characterize fasting blood sugar (FBS), GGT (15), high-density lipoprotein (HDL) triglyceride (TG), and cholesterol levels.

3.4. Definition of Metabolic Syndrome

The National Cholesterol Education Program Adult Treatment Panel III (ATP III) was considered to define metabolic syndrome (MetS) (16). Three or more of the following conditions confirmed the diagnosis of MetS: TG ≥ 150 mg/dL (or drug treatment for increased TG); waist circumference (WC) ≥ 102 cm in men and ≥ 88 cm in women; HDL-C values of < 40 mg/dL in men and < 50 mg/dL in women; increased systolic (≥ 130 mmHg) or diastolic blood pressure (≥ 85 mmHg) or the use of antihypertensive medications; and elevated fasting glucose (≥ 100 mg/dL) or the use of glucose-lowering medications.

Four groups of cardiometabolic phenotypes were determined based on the BMI cutoff point (25 kg/m²) and the presence of MetS. Then the participants were classified into four groups of MHL (BMI < 25 kg/m² and no MetS), MUHL (BMI < 25 kg/m² and MetS present), MHO (BMI ≥ 25 kg/m² and no MetS), and MUHO (BMI ≥ 25 kg/m² and MetS present).
3.5. Statistical Analysis

In this study, SPSS software version 11.5 (Chicago, IL, USA) was used for the data analysis. Continuous variables are demonstrated as mean ± standard deviation, and categorical variables are represented by frequencies (percentages). The four groups were compared using the chi-square, Kruskal-Wallis, and one-way ANOVA tests. The participants were also divided into the following serum GGT tertiles: Tertile 1: ≤ 14 U/L; Tertile 2: 15 - 23 U/L; and Tertile 3: ≥ 24 U/L. The multinomial logistic regression analysis was used to estimate the relationship between the cardiometabolic phenotype and the serum GGT tertile. Moreover, crude and adjusted odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were assessed. The effects of the intervening factors (ie, gender, age, marital status, level of education, and current smoking status) were also adjusted, and the MHL group was considered the reference group. The diagnostic value of the GGT area under the curve was calculated by the receiver-operating characteristics (ROC) curves (area under curve [AUC] and 95% CI, sensitivity, and specificity). According to the BMI classification, seven underweight participants were excluded. Finally, 1,451 subjects were included in the statistical analysis. In this study, P < 0.05 was set as the level of significance.

4. Results

4.1. Participants’ Characteristics

Table 1 presents the participants’ baseline characteristics according to their GGT tertiles. Among the three tertiles, the third tertile had the highest proportion of male and married participants. Moreover, there were significant differences in the prevalence of cardiometabolic phenotypes among the GGT tertiles (P ≤ 0.001). The highest prevalence of MHO was observed in the third tertile of GGT (Table 1). Furthermore, the mean values of FBS, TG, WC, cholesterol, HDL, SBP, DBP, and BMI showed incremental trends from the first GGT tertile to the third GGT tertile (P ≤ 0.001) (Table 1). As presented in Table 2, the third tertile had the smallest number of females (P < 0.001) as a GGT dose-dependent variable in the MHO, MUHO, and MHL classes of cardiometabolic phenotypes. Interestingly, the mean values of WC, TG, FBS, cholesterol, DBP, and SBP were higher in the MHL, MHO, and MUHO groups, representing a dose-response manner matching the GGT tertile (P < 0.05) (Table 2).

4.2. Relationship Between Serum GGT and Cardiometabolic Phenotype

The findings of the unadjusted model indicated that compared to the lowest GGT tertile, the risks of MHO and MUHO in the highest GGT tertile increased by 2.84 (95% CI 2.01 - 4.01) and 9.12 (95% CI 5.54 - 15), respectively (Table 3). After adjustment for different intervening factors (ie, age, gender, level of education, marital status, smoking, and alcohol consumption), a strong positive correlation was observed between GGT with MHO and MUHO (Table 3). The relationship was more obvious in the third GGT tertile, especially for the MUHO individuals. In Model 3, the observed OR for MUHO was 3.53 (95% CI 2.11 - 5.90) in the second GGT tertile, while it was 14.29 (8.15 - 25.08) in the third GGT tertile (Table 3). The ROC analysis was performed to differentiate between MHO and MUHO. The cutoff value of 18.5 U/L for GGT allowed us to distinguish MHO from MUHO with a sensitivity of 72.6% and a specificity of 50.7%. GGT had an AUC of 0.634 [95% CI: 0.59 - 0.67] (Figure 1).

The observed ROC curves for MHL and MUHL and relevant findings are not reported since they were not statistically significant.

5. Discussion

The main findings regarding the three cardiometabolic phenotype classes (ie, MHL, MHO, and MUHO) are as follows: The frequency of females decreased as a dose-dependent variable of the GGT tertile, indicating that the lowest frequency was observed in the third GGT tertile. In the MHL, MHO, and MUHO groups, there were significant changes in the mean WC, TG, cholesterol, FBS, DBP, SBP, and HDL levels with increasing GGT concentrations. The risk of MHO and MUHO increased according to the GGT tertile; the highest ORs were in the third GGT tertile. Such a significant correlation was more highlighted after adjusting for the intervening factors.

The present findings confirm those of a previous study, indicating a positive correlation between serum GGT and MetS after adjusting for demographics, BMI, alcohol consumption, and smoking status (17-22). Xu et al. noted that the risk of MetS increased in the highest GGT quartiles after adjusting for intervening factors (19). In another cross-sectional study, Lee et al. adjusted for age and drinking status and obtained comparable results in the highest GGT quartile (20). Although the results of these studies show that an elevated GGT level indicates an increased risk of MetS, other studies have documented the increased risk of MetS, even with a normal range of GGT (23, 24).

In most cases, the findings on the relationship between MetS and GGT levels were adjusted for BMI. Recent studies have reported a subset of overweight and obese individuals with normal metabolic profiles (25). According to some reports, metabolically-normal individuals with large
| Table 1. Participants’ Baseline Characteristics According to Gamma-glutamyl Transferase Tertile (n = 1451) $^a$, $^b$, $^c$ |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Tertile 1 $\leq$ 14 (n = 471) | Tertile 2 = 15 - 23 (n = 485) | Tertile 3 $\geq$ 24 (n = 495) | P-Value |
| Gender | | | $< 0.001$ |
| Male | 99 (21) | 255 (52.6) | 371 (74.9) |
| Female | 372 (79) | 230 (47.4) | 124 (25.1) |
| Level of education | | | $< 0.001$ |
| Illiterate | 5 (1) | 14 (2.9) | 10 (2) |
| Primary school | 14 (3) | 31 (6.4) | 40 (8.1) |
| High school | 68 (14.4) | 77 (15.9) | 112 (22.6) |
| University | 384 (81.5) | 363 (74.8) | 333 (67.1) |
| Marital status | | | $< 0.001$ |
| Married | 394 (83.7) | 420 (86.6) | 463 (93.5) |
| Single | 77 (16.3) | 65 (13.4) | 32 (6.5) |
| Cardiometabolic phenotype | | | $< 0.001$ |
| *MHL | 146 (31) | 115 (23.7) | 57 (11.5) |
| **MUHL | 3 (0.6) | 7 (1.4) | 2 (0.4) |
| ¶MHO | 290 (61.6) | 294 (60.6) | 322 (65.1) |
| ¶¶MUHO | 32 (6.8) | 69 (14.2) | 114 (23) |
| Smoking status | | | $< 0.001$ |
| Yes | 13 (2.7) | 43 (9) | 59 (11.9) |
| No | 456 (96.9) | 437 (90.1) | 434 (88) |
| Alcohol consumption | | | 0.89 |
| Yes | 1 (0.2) | 5 (1) | 3 (0.6) |
| No | 470 (99.6) | 480 (99) | 492 (99) |
| Drug use | | | |
| Yes | - | - | - |
| No | - | - | - |
| Age (y) | 41.51 ± 6.16 | 42.83 ± 7.09 | 43.21 ± 6.74 $^A$ | $< 0.001$ |
| Waist circumference (cm) | 92.08 ± 8.37 | 95.17 ± 8.9 | 98.75 ± 8.7 $^B$ | $< 0.001$ |
| Triglyceride (mg/dL) | 96.12 ± 38.40 | 118.83 ± 50.85 | 147.90 ± 77.32 $^B$ | $< 0.001$ |
| Fasting blood sugar (mg/dL) | 81.67 ± 15.93 | 86.34 ± 19.39 | 90.89 ± 23.19 $^B$ | $< 0.001$ |
| High density lipoprotein (mg/dL) | 48.35 ± 11.01 | 45.45 ± 10.35 | 43.96 ± 9.85 $^B$ | $< 0.001$ |
| Cholesterol (mg/dL) | 157.53 ± 33.98 | 166.95 ± 35.79 | 177.76 ± 37.91 $^B$ | $< 0.001$ |
| Systolic blood pressure (mm Hg) | 105.13 ± 12.73 | 110.59 ± 13.69 | 116.44 ± 14.72 $^B$ | $< 0.001$ |
| Diastolic blood pressure (mm Hg) | 70.08 ± 8.27 | 76.01 ± 8.77 | 79.27 ± 9.55 $^B$ | $< 0.001$ |
| Body mass index (kg/m$^2$) | 26.71 ± 1.64 | 27.50 ± 3.91 | 29.06 ± 4.01 $^B$ | $< 0.001$ |

$^a$ P-value, chi square test; € P-value, Kruskal Wallis; ¥ P-value, one way ANOVA; $^*$ MHL, metabolically healthy lean; $^{**}$ MUHL, metabolically unhealthy lean; $^\|$ MHO, metabolically healthy obese; $^{¶¶}$ MUHO, metabolically unhealthy obese

$^b$ The capital letter, A, denotes a significant difference between the 3rd and 1st tertiles ($P < 0.05$); and B denotes a significant difference between the 1st, 2nd, and 3rd tertiles ($P < 0.05$)

$^c$ Values are expressed as No. (%) or mean ± SD.
body sizes and metabolically-normal individuals with normal weight may experience a similar risk of chronic diseases (26). In contrast, compared to MHNW (metabolically healthy normal weight), individuals about 24% of normal-weight American adults (BMI < 25.0 kg/m²) are considered metabolically abnormal (27), thereby placing them at a higher risk for chronic diseases generally associated with elevated BMI. Understanding the effects of body size on MetS risk can have implications for public health and clinical practice. To the best of the authors’ knowledge, no study, but one, has addressed the relationship between cardiometabolic phenotype and GGT levels. The concerned study was conducted with a small sample size (n = 140) and examined the correlation between GGT levels and MHO in at-risk obese individuals who were young nondiabetic obese women (28). Although some MHNW and obese participants have an increased risk of an unhealthy phenotype, others may have remarkably stable and desirable metabolic profiles, which can be a matter of concern (29).

According to what was mentioned, it is crucial to determine reliable biomarkers to distinguish healthy subjects at risk of transition to an unhealthy metabolic con-
The main limitation of this study was that the causal inferences between serum GGT and cardiometabolic phenotypes could not be detected because of the study's cross-sectional nature. The small sample size of the MUHL participants was another limitation. On the other hand, the main strength of the present study was its unprecedented advantage of serum GGT is in the availability of this marker for the accurate identification of the MHO subjects who are at risk for cardiovascular risk factors. Therefore, GGT plays a pro-inflammatory role in mediating the interconversion of leukotriene (LT)-C4 into LT-D4, where LT-C4 is a glutathione-containing inflammatory mediator (36). Accordingly, a correlation between serum GGT and the increased risk of MetS in MUHL and MHO individuals can be found after studying the predefined and novel cardiovascular risk factors.

The main limitation of this study was that the causal inferences between serum GGT and cardiometabolic phenotypes could not be detected because of the study’s cross-sectional nature. The small sample size of the MUHL participants was another limitation. On the other hand, the main strength of the present study was its unprecedented venture in examining the relationship between GGT and cardiometabolic phenotypes in healthcare workers. The detailed mechanism of this relationship is not well-clarified. However, in addition to the mechanisms mentioned earlier, an alternative explanation could be the oxidative stress induction property of serum GGT, being a marker of oxidative stress (32, 33). Elevated serum GGT activity leads to the shift of extra glutathione into cells and glutathione metabolism, resulting in oxidative stress (19).

On the other hand, GGT contributes to drug detoxification, facilitates protein synthesis and transmembrane transportation, and inhibits oxidative stress by making cysteine available for intracellular glutathione regeneration (34). Cellular GGT can be augmented by iron during oxidative stress. In this regard, shifting the role of cellular GGT from an antioxidant to a pro-oxidant in the presence of a transition metal such as iron has been reported in experimental studies (35). The vital role of oxidative stress in the pathogenesis of MetS has been well-documented (20, 21). Moreover, GGT plays a pro-inflammatory role in mediating the interconversion of leukotriene (LT)-C4 into LT-D4, where LT-C4 is a glutathione-containing inflammatory mediator (36). Accordingly, a correlation between serum GGT and the increased risk of MetS in MUHL and MHO individuals can be found after studying the predefined and novel cardiovascular risk factors.

We believe that the strong relationship between GGT and MUHO can be attributed to the role of hepatic adipose deposition in the MUHO pathogenesis. In this regard, individuals with the MUHO phenotype had the highest WC values. Hepatic adipose deposition results in adverse metabolic consequences such as insulin resistance and inflammation, with gradual subsequent fatty infiltration of other organs (31). Elevated liver enzyme levels may indicate this hepatic adipose deposition, and MUHO individuals may have higher insulin resistance. These factors somewhat explain the biological mechanisms of the MUHO phenotype.

In this study, the ROC curves were used to assess the ability of GGT to distinguish different cardiometabolic phenotype classes. Accordingly, a cutoff value of 18.5 U/L may indicate the transition of an MHO individual to the MUHO class. The detailed mechanism of this relationship is not well-clarified. However, in addition to the mechanisms mentioned earlier, an alternative explanation could be the oxidative stress induction property of serum GGT, being a marker of oxidative stress (32, 33). Elevated serum GGT activity leads to the shift of extra glutathione into cells and glutathione metabolism, resulting in oxidative stress (19).

On the other hand, GGT contributes to drug detoxification, facilitates protein synthesis and transmembrane transportation, and inhibits oxidative stress by making cysteine available for intracellular glutathione regeneration (34). Cellular GGT can be augmented by iron during oxidative stress. In this regard, shifting the role of cellular GGT from an antioxidant to a pro-oxidant in the presence of a transition metal such as iron has been reported in experimental studies (35). The vital role of oxidative stress in the pathogenesis of MetS has been well-documented (20, 21). Moreover, GGT plays a pro-inflammatory role in mediating the interconversion of leukotriene (LT)-C4 into LT-D4, where LT-C4 is a glutathione-containing inflammatory mediator (36). Accordingly, a correlation between serum GGT and the increased risk of MetS in MUHL and MHO individuals can be found after studying the predefined and novel cardiovascular risk factors.

The main limitation of this study was that the causal inferences between serum GGT and cardiometabolic phenotypes could not be detected because of the study’s cross-sectional nature. The small sample size of the MUHL participants was another limitation. On the other hand, the main strength of the present study was its unprecedented venture in examining the relationship between GGT and cardiometabolic phenotypes in healthcare workers. The advantage of serum GGT is in the availability of this marker in routine clinical practices and its standardized measurement methods. It can be helpful for the prompt and accurate identification of the MHO subjects who are at risk.

**Table 1. Odds Ratios and 95% Confidence Intervals for Cardiometabolic Phenotype According to Serum Gamma-Glutamyl Transferase Tertiles**

| GGT (U/L), OR (95% CI) | Tertile ≤ 14 (n = 471) | Tertile 2 15-23 (n = 485) | Tertile 3 ≥ 24 (n = 495) |
|------------------------|------------------------|------------------------|------------------------|
| MUHL                   | Reference               | 2.96 (0.74 - 11.70)    | 1.70 (0.27 - 10.48)    |
|                        |                        | 1.28 (0.96 - 1.72)     | 2.84 (2.00 - 4.03)     |
|                        | Reference               | 2.73 (1.68 - 4.44)     | 9.12 (5.54 - 15.00)    |
| MUHO                   | Reference               | 2.87 (0.65 - 12.54)    | 2.27 (0.32 - 16.06)    |
|                        | Model 1: Reference      | 3.61 (0.87 - 15.18)    | 2.55 (0.36 - 17.82)    |
|                        | Model 2: Reference      | 3.61 (0.86 - 15.14)    | 2.45 (0.35 - 17.20)    |
|                        | Model 3: Reference      | 2.87 (0.65 - 12.54)    | 2.27 (0.32 - 16.06)    |
| MHO                    | Reference               | 1.55 (1.13 - 2.12)     | 3.92 (2.66 - 5.79)     |
|                        | Model 1: Reference      | 1.56 (1.14 - 2.15)     | 3.90 (2.63 - 5.78)     |
|                        | Model 3: Reference      | 1.54 (1.12 - 2.12)     | 3.93 (2.65 - 5.83)     |
| MUHO                   | Reference               | 3.40 (2.04 - 5.66)     | 13.85 (7.95 - 24.45)   |
|                        | Model 2: Reference      | 3.43 (2.06 - 5.73)     | 13.78 (7.90 - 24.08)   |
|                        | Model 3: Reference      | 3.53 (2.41 - 5.90)     | 14.29 (8.35 - 25.08)   |

*MHL was considered as a reference group; Model 1: adjusted for age and gender; Model 2: adjusted for age, gender, marital status, and level of education; Model 3: adjusted for age, gender, level of education, marital status, and smoking.
of transition to the MUHO phenotype, thereby facilitating better preventive strategies. The other strength of this study was the acquisition of data from a highly large cohort population.

5.1. Conclusions

According to the findings, it can be concluded that the prevalence of the MHO and MUHO cardiometabolic phenotypes might rise with increasing the GGT levels. Moreover, a cutoff value was set for GGT to assess the MHO subjects at the risk of transition to the MUHO phenotype; hence, GGT may act as a biomarker to reflect MetS risk. Accordingly, GGT level can be used to detect at-risk MHO individuals and administer proper interventions.

Acknowledgments

The authors would like to express their gratitude to the Research Center for Liver and Gastrointestinal Diseases, Tabriz University of Medical Sciences, for their financial support. The authors also are deeply indebted to all subjects who participated in this study. We appreciate the contribution of the investigators and the staff of the Azar cohort study and the collaboration of the Shabestar Health Center. Moreover, we would like to thank the Persian cohort study staff for their technical support.

Footnotes

Authors’ Contribution: Conception or design of the study: M. H. S., A. R. O., & S. S.; Data acquisition and analysis: N. G. & E. F.; Interpretation of data: E. F. & S. S.; Drafting the manuscript or revision: E. F., N. F., S. Z., & S. S.; All authors studied and approved the manuscript.

Conflict of Interests: The authors declare that they have affiliation with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Data Reproducibility: The data that support the findings of this study are available from the Vice Chancellor for Research; however, there are restrictions on the availability of these data, which were used under license for the present study, and are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the Vice Chancellor for Research.

Ethical Approval: The Ethics Committee of the Tabriz University of Medical Sciences, Tabriz, Iran approved this study (Code: IR.TBZMED.REC.1400.627).

Funding/Support: This study was supported by the Research Center for Liver and Gastrointestinal Diseases (Grant NO.: 67753), Tabriz University of Medical Sciences.

Informed Consent: Written informed consent was obtained from all participants.

References

1. Neuman MG, Malnick S, Chertin L. Gamma glutamyl transferase - an underestimated marker for cardiovascular disease and the metabolic syndrome. J Pharm Pharm Sci. 2020;23(1):65-74. doi: 10.3843/jpps.30923. [PubMed: 32300756].
2. Lee MY, Hyon DS, Huh JH, Kim HK, Han SK, Kim JY, et al. Association between Serum Gamma-Glutamyltransferase and Prevalence of Metabolic Syndrome Using Data from the Korean Genome and Epidemiology Study. Endocrinol Metab (Seoul). 2019;34(4):3390-7. doi: 10.3803/EM.2019.34.4.3390. [PubMed: 31847393]. [PubMed Central: PMC6935781].
3. Ko SH, Baeg MK, Han KD, Ko SY, Shin SB, Ko SH, et al. Association between gamma-glutamyltransferase and albuminuria in nondiabetic adults with normal renal function. Clin Exp Nephrol. 2017;21(5):835-41. doi: 10.1007/s10157-016-1356-7. [PubMed: 27933415].
4. Yadav D, Lee MY, Kim JY, Ryu H, Huh JH, Bae KS, et al. Combined Effect of Initial and Longitudinal Increases in gamma-Glutamyltransferase on Incident Metabolic Syndrome: ARIRANG Study. Yonsei Med J. 2017;58(4):763-9. doi: 10.3349/ymj.2017.58.4.763. [PubMed: 28540989]. [PubMed Central: PMC5447017].
5. Kang YH, Min HK, Son SM, Kim IJ, Kim YK. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract. 2007;77(2):306-13. doi: 10.1016/j.diabres.2006.11.009. [PubMed: 17530161].
6. Nebhini N, Sharma P, Pareek V, Suthar N, Jakhotia S, Gehlot M, et al. Association of Inflammatory and Liver Markers with Cardiometabolic Risk Factors in Patients with Depression. Indian J Clin Biochem. 2019;34(2):219-24. doi: 10.1007/s12229-018-0739-x. [PubMed: 31092997]. [PubMed Central: PMC6486915].
7. Park WY, Kim SH, Kim YO, Jin DC, Song HC, Choi EJ, et al. Serum Gamma-Glutamyltransferase Levels Predict Mortality in Patients With Peritoneal Dialysis. Medicine (Baltimore). 2015;94(31):e1249. doi: 10.1097/MD.0000000000001249. [PubMed: 26252284]. [PubMed Central: PMC4616583].
8. Bulusu S, Sharma M. What does serum gamma-glutamyltransferase tell us as a cardiometabolic risk marker? Ann Clin Biochem. 2016;53(3):312-32. doi: 10.1177/0004563215597010. [PubMed: 26193450].
9. Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2015;71(1-2):31-7. doi: 10.1016/j.ypmed.2015.01.011. [PubMed: 25371855].
10. Onat A, Cán G, Ornek E, Ciečk G, Ayhan E, Dogan Y. Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012;20(4):842-8. doi: 10.1038/oby.2011.136. [PubMed: 2263402].
11. Hong NS, Kim JG, Lee YM, Kim HW, Kam S, Kim KY, et al. Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: a cross-sectional study. BMC Endocr Disord. 2014;14(1):57. doi: 10.1186/1472-6823-14-57. [PubMed: 25015107]. [PubMed Central: PMC407621].

Hepat Mon. 2022; 22(1):et21021.
12. Lippi G, Targher G, Montagana M, Salvagno GL, Guidi GC. Relationship between gamma-glutamyltransferase, lipids and lipoprotein(a) in the general population. Clin Chim Acta. 2007;384(1-2):263–6. doi: 10.1016/j.cca.2007.06.005. [PubMed: 17605212].

13. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshkar AA, Hekmatdoost A, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study); Rationale, Objectives, and Design. Am J Epidemiol. 2018;187(4):547–55. doi: 10.1093/aje/kwx314. [PubMed: 29445581]. [PubMed Central: PMC6279098].

14. Farhang S, Faramarzi E, Amini Sani N, Poustchi H, Ostadrabhi A, Alizadeh BZ, et al. Cohort Profile: The AZAR cohort, a health-oriented research model in areas of major environmental change in Central Asia. Int J Epidemiol. 2019;48(2):382–382h. doi: 10.1093/ije/dyy215. [PubMed: 30445493].

15. Bergmeyer H. Methoden der enzymatischen Analyse, vols 1 and 2. Chemie, Weinheim/Bergstr. 1974:4670–4.

16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. doi: 10.1161/CIRCULATION. AHA.109.192644. [PubMed: 19805654].

17. Tao L, Li X, Zhu H, Gao Y, Luo Y, Wang W, et al. Association between gamma-glutamyl transferase and metabolic syndrome: a cross-sectional study of an adult population in Beijing. Int J Environ Res Public Health. 2013;10(1):552–40. doi: 10.3390/ijerph10010523. [PubMed: 2471318]. [PubMed Central: PMC3681258].

18. Wang S, Zhang J, Zhu L, Song L, Meng Z, Jia Q, et al. Association between liver function and metabolic syndrome in Chinese men and women. Sci Rep. 2017;7:44844. doi: 10.1038/srep44844. [PubMed: 28317840]. [PubMed Central: PMC5557848].

19. Xu Y, Bi YF, Xu M, Huang Y, Lu WY, Gu YF, et al. Cross-sectional and longitudinal association of serum alanine aminotransaminase and gamma-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J Diabetes. 2011;3(1):38–47. doi: 10.1111/j.1753-0440.2010.00011.x. [PubMed: 20199427].

20. Lee MY, Koh SB, Koh JH, Nam SM, Shin JY, Shin YG, et al. Relationship between gamma-glutamyl transferase and metabolic syndrome in a Korean population. Diabet Med. 2008;25(4):469–75. doi: 10.1111/j.1464-5491.2008.02455.x. [PubMed: 18346061].

21. Hwang AC, Lin YC, Liu PT, Kao YM, Chen JD. Synergistic effect of gamma-glutamyltransferase and obesity on metabolic syndrome, independent of hepatic steatosis. Ann Epidemiol. 2012;22(12):786–790. doi: 10.1016/j.annepidem.2012.09.002. [PubMed: 23109060].

22. Oh HJ, Kim TH, Sohn YW, Kim SY, Oh YR, Cho EY, et al. Association of serum alanine aminotransaminase and gamma-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol. 2011;17(1):27–36. doi: 10.3350/kjhp.2011.17.1.27. [PubMed: 21494075]. [PubMed Central: PMC304067].

23. Ryu S, Chang Y, Woo HY, Yoo SH, Choi NK, Lee WY, et al. Longitudinal increase in gamma-glutamyltransferase within the reference interval predicts metabolic syndrome in middle-aged Korean men. Metabolism. 2010;59(5):683–9. doi: 10.1016/j.metabol.2009.08.024. [PubMed: 19922966].

24. Suh BS. The Association between Serum Gamma-Glutamyltransferase within Normal Levels and Metabolic Syndrome in Office Workers: A 4-Year Follow-up Study. Korean J Fam Med. 2012;33(1):51–8. doi: 10.4082/kjfkm.2012.33.1.51. [PubMed: 22745888]. [PubMed Central: PMC3832422].

25. Bradshaw PT, Monda KL, Stevens J. Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the Atherosclerosis Risk in Communities Study. Obesity (Silver Spring). 2013;21(3):1203–9. doi: 10.1002/oby.20248. [PubMed: 23505087]. [PubMed Central: PMC4170589].

26. Bintoro BS, Fan YC, Chou CC, Chien KL, Bai CH. Metabolic Unhealthiness Increases the Likelihood of Having Metabolic Syndrome Components in Normoweight Young Adults. Int J Environ Res Public Health. 2019;16(18):3258. doi: 10.3390/ijerph160183258. [PubMed: 3149867].

27. Chung YH, Hwang SH, Lee SW, Lee YG, Hong YS, et al. Association of serum gamma-glutamyltransferase activity with oxidative stress rather than syntax score. J Atheroscler Thromb. 2017;24(5):449–57. doi: 10.2217/bmm-2016-0332. [PubMed: 2862610].

28. Mankowska-Cyl A, Krintus M, Rajewski P, Sypniewska G. Gamma-glutamyl transferase activity as a surrogate biomarker of metabolic health status in young nondiabetic obese women. Biomark Med. 2017;11(5):349–57. doi: 10.2217/bmm-2016-0312. [PubMed: 2862610].

29. Blumber M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol. 2010;21(1):38–43. doi: 10.1097/MOL.0b013e3283346ccc. [PubMed: 19915462].

30. Xie J, Zhang S, Yu X, Yang Y, Liu Z, Yuan G, et al. Association between Liver Enzymes with Metabolically Unhealthy Obese Phenotype. Lipids Health Dis. 2019;18(1):3–8. doi: 10.1186/s12944-018-0847-9. [PubMed: 30034916]. [PubMed Central: PMC6106819].

31. D’Adamo E, Cali AM, Weiss R, Santoro N, Pierpoint B, Northrup V, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33(8):1817–22. doi: 10.2377/jc.2010-0284. [PubMed: 20668154]. [PubMed Central: PMC2909068].

32. Lee DH, Blomhoff R, Jacobs DJ. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38(6):353–9. doi: 10.1080/10715760410001694026. [PubMed: 15346644].

33. Kugelman A, Choy HA, Liu R, Shi MM, Gozal E, Forman HJ. Gamma-Glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells. Am J Respir Cell Mol Biol. 1994;10(1):58–62. doi: 10.1165/ajrcmb.1994.10.1.58. [PubMed: 7946187].

34. Ucar H, Gur M, Gozukara MY, Kalkan GY, Baykan AO, Turkgolu C, et al. Gamma glutamyl transferase activity is independently associated with oxidative stress rather than syntax score. Scand J Clin Lab Invest. 2015;75(1):7–12. doi: 10.1080/00365513.2014.954140. [PubMed: 25180444].

35. Drozdz R, Parmentier C, Hackad H, Leroy P, ‘erard Siest G, Wellman MA. γ-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radical Biol Med. 1998;25(7):786–92. doi: 10.1016/S0891-5849(98)00270-0. [PubMed: 9589186].

36. Javarappa D, Nagalakshmi CS, Savadi B, Santosh N, Shaikh SB. Can Gamma Glutamyl Transferase Serve as a Marker to Predict the Risk of Metabolic Syndrome in Patients with Type 2 Diabetes Mellitus? Indian J Med Biochem. 2009;23(3):347–9. doi: 10.3340/pjournals.0054-0116. [PubMed: 19922966].
Table 2. Demographic, Anthropometric, and Biochemical Factors Regarding Gamma-Glutamyl Transferase Tertile Stratified by Cardiometabolic Phenotype

| MHL | Gender | GGT (UL/L) | P-Value |
|-----|--------|------------|---------|
|     |        | Tertile 1 ≤ 14 (n = 471) | Tertile 2 = 15 - 23 (n = 485) | Tertile 3 ≥ 24 (n = 495) |
|     | Male   | 35 (24) | 83 (72.2) | 46 (80.7) |
|     | Female | 111 (76) | 32 (22.1) | 11 (19.3) |
|     | Age (y) | 40.99 ± 6.70 | 41.60 ± 6.78 | 41.28 ± 7.21 |
|     | Waist circumference (cm) | 85.09 ± 5.70 | 87.25 ± 5.82 | 86.84 ± 5.30 |
|     | Triglyceride (mg/dL) | 86.09 ± 12.16 | 107.10 ± 47.13 | 106.08 ± 38.56 |
|     | Fasting blood sugar (mg/dL) | 80.78 ± 32.16 | 107.10 ± 47.13 | 106.08 ± 38.56 |
|     | Cholesterol (mg/dL) | 152.14 ± 10.99 | 182 ± 86.48 | 194.14 ± 34.0 |
|     | Systolic blood pressure (mm Hg) | 159.63 ± 13.17 | 167.42 ± 37.19 | 160.5 ± 55.86 |
|     | Diastolic blood pressure (mm Hg) | 85.33 ± 5.73 | 78.85 ± 15.38 | 67.50 ± 3.53 |

| MUHL | Gender | GGT (UL/L) | P-Value |
|------|--------|------------|---------|
|      |        | Tertile 1 ≤ 14 (n = 471) | Tertile 2 = 15 - 23 (n = 485) | Tertile 3 ≥ 24 (n = 495) |
|      | Male   | 35 (24) | 83 (72.2) | 46 (80.7) |
|      | Female | 111 (76) | 32 (22.1) | 11 (19.3) |
|      | Age (y) | 40.99 ± 6.70 | 41.60 ± 6.78 | 41.28 ± 7.21 |
|      | Waist circumference (cm) | 85.09 ± 5.70 | 87.25 ± 5.82 | 86.84 ± 5.30 |
|      | Triglyceride (mg/dL) | 86.09 ± 12.16 | 107.10 ± 47.13 | 106.08 ± 38.56 |
|      | Fasting blood sugar (mg/dL) | 80.78 ± 32.16 | 107.10 ± 47.13 | 106.08 ± 38.56 |
|      | Cholesterol (mg/dL) | 152.14 ± 10.99 | 182 ± 86.48 | 194.14 ± 34.0 |
|      | Systolic blood pressure (mm Hg) | 159.63 ± 13.17 | 167.42 ± 37.19 | 160.5 ± 55.86 |
|      | Diastolic blood pressure (mm Hg) | 85.33 ± 5.73 | 78.85 ± 15.38 | 67.50 ± 3.53 |

| MHO | Gender | GGT (UL/L) | P-Value |
|-----|--------|------------|---------|
|     |        | Tertile 1 ≤ 14 (n = 471) | Tertile 2 = 15 - 23 (n = 485) | Tertile 3 ≥ 24 (n = 495) |
|     | Male   | 35 (24) | 83 (72.2) | 46 (80.7) |
|     | Female | 111 (76) | 32 (22.1) | 11 (19.3) |
|     | Age (y) | 40.99 ± 6.70 | 41.60 ± 6.78 | 41.28 ± 7.21 |
|     | Waist circumference (cm) | 85.09 ± 5.70 | 87.25 ± 5.82 | 86.84 ± 5.30 |
|     | Triglyceride (mg/dL) | 86.09 ± 12.16 | 107.10 ± 47.13 | 106.08 ± 38.56 |
|     | Fasting blood sugar (mg/dL) | 80.78 ± 32.16 | 107.10 ± 47.13 | 106.08 ± 38.56 |
|     | Cholesterol (mg/dL) | 152.14 ± 10.99 | 182 ± 86.48 | 194.14 ± 34.0 |
|     | Systolic blood pressure (mm Hg) | 159.63 ± 13.17 | 167.42 ± 37.19 | 160.5 ± 55.86 |
|     | Diastolic blood pressure (mm Hg) | 85.33 ± 5.73 | 78.85 ± 15.38 | 67.50 ± 3.53 |
Systolic blood pressure (mm Hg) | 106.18 ± 12.71 | 109.65 ± 12.97 | 114.90 ± 14.21 | ¥ < 0.001
---|---|---|---|---
Diastolic blood pressure (mm Hg) | 73.78 ± 8.25 | 75.67 ± 8.78 | 78.43 ± 9.45 | ¥ < 0.001

MUHO

| Gender | € < 0.001 |
|---|---|
| Male | 5 (15.6) | 26 (37.7) | 84 (73.7) |
| Female | 27 (84.4) | 43 (62.3) | 30 (26.3) |
| Age (y) | 41.06 ± 5.82 | 44.90 ± 6.80 | 44.81 ± 6.61 | ¥ < 0.01 |
| Waist circumference (cm) | 99.57 ± 5.61 | 100.81 ± 7.57 | 105.38 ± 8.12 | ¥ 0.009 |
| Triglyceride (mg/dL) | 142.56 ± 57.20 | 165.40 ± 61.74 | 206.84 ± 93.17 | ¥ 0.05 |
| Fasting blood sugar (mg/dL) | 84.31 ± 12.14 | 101.15 ± 39.57 | 106.79 ± 38.46 | ¥ < 0.001 |
| High density lipoprotein (mg/dL) | 40.78 ± 7.00 | 40.78 ± 8.59 | 39.71 ± 8.85 | ¥ 0.65 |
| Cholesterol (mg/dL) | 162.75 ± 38.58 | 174.55 ± 37.09 | 181.41 ± 39.59 | ¥ < 0.001 |
| Systolic blood pressure (mm Hg) | 112.84 ± 14.20 | 117.71 ± 14.79 | 124.33 ± 15.68 | ¥ < 0.001 |
| Diastolic blood pressure (mm Hg) | 78.37 ± 8.70 | 80.43 ± 8.97 | 84.08 ± 8.75 | ¥ 0.001 |

* € P-value, chi-square test; €€ P-value, Kruskal Wallis; ¥ P-value, one way ANOVA; ¶MHL, metabolically healthy lean; ¶¶MUHL, metabolically unhealthy lean; ¶¶¶MHO, metabolically healthy obese; ¶¶¶¶MUHO, metabolically unhealthy obese

The capital letter, A, denotes a significant difference between the 3rd and 1st tertiles (P < 0.05); B denotes a significant difference between the 1st, 2nd, and 3rd tertiles (P < 0.05), and D denotes a significant difference between the 1st, 2nd, and 3rd tertiles (P < 0.05).

Values are expressed as No. (%) or mean ± SD.